RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, develops pharmaceuticals from Thymosin beta 4 (Tß4) for tissue protection, repair, and regeneration. The company is developing RGN-259, a sterile and preservative-free eye drop that has completed Phase 3 clinical trial for the treatment of dry eye syndrome and neurotrophic keratitis. It has strategic partnerships with Lee's Pharmaceut...
RegeneRx Biopharmaceuticals reported revenue of $76,761 for fiscal year 2022, about flat from fiscal year 2021, and net income of -$1.73 million. In Q1 2023 (the quarter ended March 31, 2023) revenue was $19,190, about flat from a year before.
Figures from company filings; latest fiscal year ended December 31, 2022.
No profile data available.